Diabetes Drugs Ref

Diabetes Drugs Reference — evidence-based pharmacology reference for diabetes drug classes. Based on NICE NG28 2022, ADA Standards of Care 2024, and SIGN 154.
FREE — no purchase needed:
— SGLT2 Inhibitors: empagliflozin, dapagliflozin, canagliflozin, ertugliflozin with doses, CV outcomes and renal thresholds
FULL ACCESS — £14.99/year unlocks:
— GLP-1 Receptor Agonists: semaglutide, liraglutide, dulaglutide, tirzepatide
— DPP-4 Inhibitors: sitagliptin, linagliptin, alogliptin, vildagliptin
— Metformin: doses, eGFR thresholds, B12 monitoring
— Sulfonylureas: gliclazide, glipizide, glibenclamide
— Insulin: basal, bolus, premixed, ultra-long analogues
— Thiazolidinediones, Meglitinides, Alpha-glucosidase inhibitors
— Prescribing Guide: renal dosing table, contraindications, monitoring
— HbA1c Targets: individualised targets by patient group
— CV Outcomes Trials: EMPA-REG, LEADER, DECLARE, DAPA-HF, REWIND, SURPASS
— Hypoglycaemia Management: severity grading, treatment protocol
— Sick Day Rules: SADMAN, JBDS inpatient protocol
— Special Situations: pregnancy, CKD, elderly, perioperative
— References: 25+ tappable citations, NICE, NEJM, Lancet, ADA
Subscription renews automatically at £14.99/year unless cancelled at least 24 hours before the end of the current period. Manage in App Store Settings > Subscriptions.
For use by qualified healthcare professionals only. Always verify doses against the current BNF and SmPC before prescribing.